Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiation is a research paper published in Leukemia (2024). On theSindex it has a DataRank of 0.434. It has been cited 17 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.434
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Leukemia and Lymphoma Society
Grant: CDP 2331-20
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: R01-CA197870
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: R35-CA197734
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: K12-CA133250
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: R01HL170038
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: K23-CA178183
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: K23-HL155890
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Grant: R01HL1168045
National Institutes of Health
Grant: 1R01HL170038-01
Novel patient biomarkers and mechanisms of TKI associated Cardiotoxicity
National Institutes of Health
Grant: 5R01CA197870-03
Improving BTK Directed Therapy for CLL
National Institutes of Health
Grant: 4K23CA178183-04
Targeted Therapies and Mechanisms of Resistance in Chronic Lymphocytic Leukemia
National Institutes of Health
Grant: 5R35CA197734-06
Targeted Therapy for Leukemia
National Institutes of Health
Grant: 2K12CA133250-16
OSU K12 Training Grant in Oncology
National Institutes of Health
Grant: 5K23HL155890-02
Early Detection and Mechanisms of Cancer Immunotherapy Associated Cardiotoxicity
National Institutes of Health
Grant: 1R01HL168045-01A1
Therapeutic Strategies to Mitigate Toxicities of Anthracycline-Based Therapeutics
Leukemia and Lymphoma Society
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute
Robert Wood Johnson Foundation (Harold Amos) - American Heart Association Program Grant D. Warren Brown Foundation Four Winds Foundation Connie Brown CLL Foundation
Conquer Cancer, American Society of Clinical Oncology Career Development Award
FWCI
4.68
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals